AbbVie Joins US Pilot Program to Test Drug Discount Rebates
US drugmaker AbbVie will participate in a government pilot program starting January 1, 2027, to test a new rebate system for discounted medicines under the 340B program, reuters.com reported on October 2.
- AbbVie joins a federal pilot program beginning January 1, 2027, to test a new rebate system for discounted medications under the 340B program.
- Eligible healthcare providers will submit claims through a platform called Beacon to secure 340B pricing on the cancer drug Imbruvica, irritable bowel syndrome treatment Linzess, and antipsychotic drug Vraylar.
- Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also approved to take part in the federal pilot alongside AbbVie.
Participation in the 340B Rebate Pilot Starting January 1 2027
The federal 340B program assists hospitals and clinics serving low-income patients in purchasing medicines at a discount. Under the new model tested in the pilot, eligible healthcare providers will submit claims through a platform known as Beacon. This process is designed to obtain 340B pricing on AbbVie medications including the cancer drug Imbruvica, the irritable bowel syndrome treatment Linzess, and the antipsychotic drug Vraylar, reuters.com reported.
AbbVie stated that it will provide participating healthcare groups with free access to the Beacon system. The company also committed to offering customer service and specialized assistance for providers encountering operational difficulties during the rollout. Throughout the process, AbbVie plans to work closely with federal health regulators and healthcare providers.
Rebate Test Aims to Improve Pricing Transparency
The rebate test aims to improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect, according to the company. Beyond AbbVie, the federal pilot includes other pharmaceutical companies. Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are among the firms approved for participation in the initiative, reuters.com reported.
Reporting on the announcement was handled by Kamal Choudhury in Bengaluru, with editing by Shilpi Majumdar.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.